Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vildagliptin · 1 trial · 1 indication
The 24 hour WMG was measured after 2 weeks of placebo treatment, and again after 2 weeks of vildagliptin treatment. Glucose was measured over a 24 hour period by having participants wear two continuous glucose monitors (CGM), which produced an average glucose value approximately every 5 minutes. Using these values, the concentration of glucose was calculated from Area Under the Curve 0-24 hours (AUC 0-24hr), and was expressed as 24 hour WMG.
| Arm | Type | Description |
|---|---|---|
| Placebo → Vildagliptin | EXPERIMENTAL | Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily |
| Name | Type | Description |
|---|---|---|
| Vildagliptin | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of type 2 diabetes mellitus on a clinical regimen that is metformin alone, up to a maximum of 3 gram per day, on a background of lifestyle measures, and has a Hemoglobin A1C at screening of \> 7%. * If on antihyperglycemic therapy with both metformin and sul...
Vildagliptin is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its effects on glucose control in patients with this condition.
Vildagliptin is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus.
Vildagliptin is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of Type 2 Diabetes Mellitus, with one completed Phase 1 trial involving 25 participants.
Vildagliptin has one completed clinical trial registered under NCT01537120, titled "Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)." This Phase 1 study enrolled 25 adults aged 18 years and older with Type 2 Diabetes Mellitus and was not randomized or double-blinded.
Vildagliptin is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of Type 2 Diabetes Mellitus. The drug has completed one early-stage clinical trial, but it remains under investigation and has not received regulatory approval for commercial use.